Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 4/20 | 0.44 |
| ▸ | MAOB | P27338 | 3/20 | 0.44 |
| ▸ | NISCH | Q9Y2I1 | 3/20 | 0.44 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | TAAR1 | Q96RJ0 | 4/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.41 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.41 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.41 |
| ▸ | CTSA | P10619 | 1/20 | 0.40 |
| ▸ | PTPRB | P23467 | 1/20 | 0.39 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.39 |
| ▸ | SLC18A2 | Q05940 | 1/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14962698 | 1.00 | MAOA (0.44) | MAOAMAOBNISCHPDPK1LMNA | |
| SCHEMBL30230276 | 0.86 | MAPKAPK2 (0.43) | LMNASLC6A2SLC6A4SLC6A3CYP2D6 | |
| SCHEMBL14962659 | 0.83 | PDPK1 (0.41) | MAOAPDPK1LMNATAAR1SLC6A2 | |
| SCHEMBL20196263 | 0.83 | PDPK1 (0.41) | MAOAPDPK1LMNATAAR1SLC6A2 | |
| SCHEMBL14962671 | 0.83 | PDPK1 (0.41) | MAOAPDPK1LMNATAAR1SLC6A2 | |
| SCHEMBL17480207 | 0.83 | LOXL2 (0.51) | LMNATAAR1SLC6A2SLC6A3CYP2A6 | |
| SCHEMBL16015558 | 0.81 | ADRB2 (0.39) | LMNASLC6A2SLC6A4ADORA2APTPRB | |
| SCHEMBL14968534 | 0.81 | ADRB2 (0.56) | LMNASLC6A2SLC6A4CYP2A6PTPRB | |
| SCHEMBL19200381 | 0.81 | LMNA (0.39) | MAOAPDPK1LMNATAAR1SLC6A2 | |
| SCHEMBL7610883 | 0.81 | ADRB3 (0.45) | PDPK1LMNAPKMCTSAPTPRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3327027-B1 | CYTOTOXIC PEPTIDES AND ANTIBODY DRUG CONJUGATES THEREOF | PFIZER (US) | 2021-01-06 | — | — | EP | disclosed |
| EP-2780039-B9 | CYTOTOXIC PEPTIDES AND ANTIBODY DRUG CONJUGATES THEREOF | PFIZER (US) | 2018-04-18 | — | — | EP | disclosed |
| EP-2780039-B1 | CYTOTOXIC PEPTIDES AND ANTIBODY DRUG CONJUGATES THEREOF | PFIZER (US) | 2017-11-29 | — | — | EP | disclosed |
| US-20170216452-A1 | ANTIBODIES AND ANTIBODY FRAGMENTS FOR SITE-SPECIFIC CONJUGATION | PFIZER INC. | 2017-08-03 | — | — | US | disclosed |
| WO-2017093845-A1 | ANTIBODIES AND ANTIBODY FRAGMENTS FOR SITE-SPECIFIC CONJUGATION | PFIZER INC. (US) | 2017-06-08 | — | — | WO | disclosed |
| US-20160168195-A1 | OLIGOPEPTIDES AND PROCESS FOR PREPARATION THEREOF | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2016-06-16 | — | — | US | disclosed |
| WO-2016055907-A1 | SYNERGISTIC AURISTATIN COMBINATIONS | PFIZER INC. (US) | 2016-04-14 | — | — | WO | disclosed |
| US-9249186-B2 | Cytotoxic peptides and antibody drug conjugates thereof | PFIZER INC. (US) | 2016-02-02 | — | — | US | disclosed |
| US-20150307551-A1 | CYTOTOXIC PEPTIDES AND ANTIBODY DRUG CONJUGATES THEREOF | PFIZER INC. | 2015-10-29 | — | — | US | disclosed |
| US-9138486-B2 | Cytotoxic peptides and antibody drug conjugates thereof | PFIZER INC. (US) | 2015-09-22 | — | — | US | disclosed |
| US-20140363452-A1 | CYTOTOXIC PEPTIDES AND ANTIBODY DRUG CONJUGATES THEREOF | PFIZER INC. | 2014-12-11 | — | — | US | disclosed |
| US-8828401-B2 | Cytotoxic peptides and antibody drug conjugates thereof | PFIZER INC. (US) | 2014-09-09 | — | — | US | disclosed |
| WO-2013105013-A1 | MUTANT ANTIBODIES AND CONJUGATION THEREOF | COVX TECHNOLOGIES IRELAND LIMITED (IE) | 2013-07-18 | — | — | WO | disclosed |
| WO-2013072813-A2 | CYTOTOXIC PEPTIDES AND ANTIBODY DRUG CONJUGATES THEREOF | PFIZER INC. (US) | 2013-05-23 | — | — | WO | disclosed |
| US-20130129753-A1 | CYTOTOXIC PEPTIDES AND ANTIBODY DRUG CONJUGATES THEREOF | PFIZER INC. (US) | 2013-05-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150307551-A1 | CYTOTOXIC PEPTIDES AND ANTIBODY DRUG CONJUGATES THEREOF | NGLY1, CD47, CD81 | MAOA 4722/4885MAOB 4659/4885NISCH 3984/4885 |
| US-20140363452-A1 | CYTOTOXIC PEPTIDES AND ANTIBODY DRUG CONJUGATES THEREOF | NGLY1, CD47, CD81 | MAOA 4722/4885MAOB 4659/4885NISCH 3984/4885 |
| US-20160168195-A1 | OLIGOPEPTIDES AND PROCESS FOR PREPARATION THEREOF | NGLY1, VIP, PREP | MAOA 4308/4885MAOB 4034/4885NISCH 3392/4885 |
| US-20130129753-A1 | CYTOTOXIC PEPTIDES AND ANTIBODY DRUG CONJUGATES THEREOF | NGLY1, CD47, CD81 | MAOA 4722/4885MAOB 4659/4885NISCH 3984/4885 |
| US-20170216452-A1 | ANTIBODIES AND ANTIBODY FRAGMENTS FOR SITE-SPECIFIC CONJUGATION | DNPEP, PA2G4, CD2BP2 | MAOA 3820/4885MAOB 3718/4885NISCH 4840/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.